Abstract
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is thought to play a critical role in tumor growth and metastasis. Consequently, anti-VEGF therapies are being actively investigated as potential anti-cancer treatments, either as alternatives or adjuncts to conventional chemo or radiation therapy. Among the techniques used to block the VEGF pathway are: 1) neutralizing monoclonal antibodies against VEGF or its receptor, 2) small molecule tyrosine kinase inhibitors of VEGF receptors, 3) soluble VEGF receptors which act as decoy receptors for VEGF, and 4) ribozymes which specifically target VEGF mRNA. Recent evidence from phase III clinical trials led to the approval of bevacizumab, an anti-VEGF monoclonal antibody, by the FDA as first line therapy in metastatic colorectal carcinoma in combination with other chemotherapeutic agents. However, may challenges still remain, and the role of anti-VEGF therapy in the treatment of other solid tumors remains to be elucidated. The aim of this article is to review the progress of clinical investigations involving VEGF inhibitors in the treatment of different types of solid tumors.
Keywords: tyrosine kinase, VEGFR-1, angiogenesis, Tumor, Monoclonal antibodies, Ribozymes
Current Pharmaceutical Design
Title: VEGF Inhibitors in Cancer Therapy
Volume: 12 Issue: 3
Author(s): Adela R. Cardones and Lionel L. Banez
Affiliation:
Keywords: tyrosine kinase, VEGFR-1, angiogenesis, Tumor, Monoclonal antibodies, Ribozymes
Abstract: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is thought to play a critical role in tumor growth and metastasis. Consequently, anti-VEGF therapies are being actively investigated as potential anti-cancer treatments, either as alternatives or adjuncts to conventional chemo or radiation therapy. Among the techniques used to block the VEGF pathway are: 1) neutralizing monoclonal antibodies against VEGF or its receptor, 2) small molecule tyrosine kinase inhibitors of VEGF receptors, 3) soluble VEGF receptors which act as decoy receptors for VEGF, and 4) ribozymes which specifically target VEGF mRNA. Recent evidence from phase III clinical trials led to the approval of bevacizumab, an anti-VEGF monoclonal antibody, by the FDA as first line therapy in metastatic colorectal carcinoma in combination with other chemotherapeutic agents. However, may challenges still remain, and the role of anti-VEGF therapy in the treatment of other solid tumors remains to be elucidated. The aim of this article is to review the progress of clinical investigations involving VEGF inhibitors in the treatment of different types of solid tumors.
Export Options
About this article
Cite this article as:
Cardones R. Adela and Banez L. Lionel, VEGF Inhibitors in Cancer Therapy, Current Pharmaceutical Design 2006; 12 (3) . https://dx.doi.org/10.2174/138161206775201910
DOI https://dx.doi.org/10.2174/138161206775201910 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Penetrating Peptides and the Mechanisms for Intracellular Entry
Current Pharmaceutical Biotechnology Indole Derivatives as Anti-Tubercular Agents: An Overview on their Synthesis and Biological Activities
Current Medicinal Chemistry Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry HIV-1 Rev Multimerization: Mechanism and Insights
Current HIV Research Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Current Cancer Drug Targets Emergence of Nanomedicine as Cancer Targeted Magic Bullets: Recent Development and Need to Address the Toxicity Apprehension
Current Drug Discovery Technologies Tissue-Specific Methylation of Long Interspersed Nucleotide Element-1 of Homo Sapiens (L1Hs) During Human Embryogenesis and Roles in Neural Tube Defects
Current Molecular Medicine CASC15: A Tumor-Associated Long Non-Coding RNA
Current Pharmaceutical Design Treatment of Chronic Hypercalcemia
Medicinal Chemistry PiWi RNA in Neurodevelopment and Neurodegenerative Disorders
Current Molecular Pharmacology Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Biodistribution and Safety Assessment of Bladder Cancer Specific Recombinant Oncolytic Adenovirus in Subcutaneous Xenografts Tumor Model in Nude Mice
Current Gene Therapy MRI Evaluation Using DWI and T2WI of Residual Lymph Nodes in patients Affected by Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
Current Medical Imaging Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Evaluation of Interactions Between Platinum-/Ruthenium-Based Anticancer Agents and Human Serum Albumin: Development of HSA Carrier for Metal-Based Drugs
Current Pharmaceutical Design Retinoids in Cancer Chemoprevention
Current Cancer Drug Targets